Navigation Links
Combination of Tratuzumab and Chemotherapy Yields Better Results for Breast Cancer

A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.

At the ESMO Conference Lugano, Issa Dahabreh from the University of Athens reported the results of a meta-analysis of 5 trials involving more than 13,000 women whose breast cancer was amenable to surgery.

All the trials compared disease-free survival, overall survival and the risk of locoregional and distant recurrence of breast cancer in women given adjuvant chemotherapy alone or chemotherapy plus trastuzumab, after breast surgery.

Up to a quarter of all breast cancers express large amounts of the HER2 protein or carry multiple copies of the HER2 gene. Those cancers tend to be associated with aggressive disease, a higher likelihood of recurrence and a decreased response to treatment. Trastuzumab is a monoclonal antibody that directly targets part of the HER2 tyrosine kinase receptor.

The results showed that combining trastuzumab with chemotherapy results in a -34% reduction in mortality and a 38% increase in disease-free survival, Dahabreh said. Those survival benefits were accompanied by decreases in the risk of both locoregional and distant recurrences of the cancer.

Taken together, these results confirm that the administration of trastuzumab in combination with chemotherapy should be the standard choice for the treatment of women with HER2 positive early stage disease, especially those with limited cardiovascular comorbidities, Dahabreh said.

This is the first meta-analysis of current published trials on the adjuvant use of trastuzumab. The results are of great clinical value since they indicate that treatment with trastuzumab results in major survival benefit in women with an aggressive disease subtype.

The level of effectiveness demonstrated by this ana lysis is largely unprecedented in the treatment of solid tumors, the authors say, and highlights the potential of implementing targeted agents with cytotoxic chemotherapy.

More information about ECLU is available at http: www.esmo.org/activities/ecluconference/.


'"/>




Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Drug Combinations May Boost Stroke Risk
3. Combination therapy to treat breast cancer
4. Combination regime may work against prostate cancer
5. Smoking and Breast Cancer - A Deadly Combination
6. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
7. A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer
8. Combination Therapy Effective In Improving Lung Cancer Survival
9. Combination Therapy Found To Improves Stroke Recovery
10. Combination Therapy Found To Be More Effective In Treating Brain Cancer
11. Combination of Clopidogrel-aspirin is better for preventing stroke than only aspirin
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2016)... ... ... This Mother’s Day kicks off the start of an important week not just ... takes place May 8-May 14. , Throughout the celebration, the U.S. Department of ... their health a top priority. Women everywhere are being encouraged to take steps toward ...
(Date:5/6/2016)... MOOREFIELD, W.V. (PRWEB) , ... May 06, 2016 , ... ... by WestBow Press) shares accounts of dying patients who have allowed those holding vigil ... June E. Kuykendall, RN, BSN, CHPN, hopes to help readers spiritually and practically gain ...
(Date:5/5/2016)... Aliso Viejo, CA (PRWEB) , ... May 05, 2016 , ... ... use in Final Cut Pro X. Drag and drop a TransWipe preset between two ... project. Choose from smooth corner wipes to colored panels with customizable color and orientation ...
(Date:5/5/2016)... ... May 05, 2016 , ... Pivot ... the industry’s gold standard KLAS Performance Report, Epic Consulting 2016 - ... organizations that specialize in consulting services for electronic health record (EHR) solutions from ...
(Date:5/5/2016)... ... May 05, 2016 , ... Textile Exchange is ... (RWS) for public stakeholder review. The stakeholder review is an important opportunity for interested ... goals and delivers value to the wool industry., The RWS is intended to be ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016  It,s time for an upgrade. There are many medical recorders ... 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix ... a world class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... , May 4, 2016 ... of Jerusalem announced today that it had signed ... BioTheryX, Inc. , developer of novel protein degradation and ... development and commercialization of drug candidates representing first-in-class therapy ... license were not disclosed. The novel technology ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Multiple Myeloma ...  report to their offering.       ... Multiple Myeloma Market and Competitive Landscape Highlights ... pipeline products, Multiple Myeloma epidemiology, Multiple Myeloma ...
Breaking Medicine Technology: